This trial is evaluating whether Durvalumab will improve 1 primary outcome and 5 secondary outcomes in patients with Carcinoma, Hepatocellular. Measurement will happen over the course of No timeframe.
This trial requires 877 total participants across 3 different treatment groups
This trial involves 3 different treatments. Durvalumab is the primary treatment being studied. Participants will be divided into 2 treatment groups. Some patients will receive a placebo treatment. The treatments being tested are in Phase 3 and have had some early promising results.
"The most common treatments for carcinoma, hepatocellular include surgery, radiation, chemotherapy, and targeted therapy. Other options may include hepatic artery embolization, immunotherapy, and liver transplantation." - Anonymous Online Contributor
"In our case study the following signs was detected: pain, jaundice, hematemesis, constipation, dyspepsia and increased erythrocyte sedimentation rate. Among the signs, the most obvious are gastrointestinal and hepatic.\n" - Anonymous Online Contributor
"The total number of cases of carcinoma hepatocellular in the United States is increasing yearly, and the 5-year rate continues to rise. Overall, men were at an increased risk compared with women, and for all ages, Hispanics were at increased risk." - Anonymous Online Contributor
"The cause of hepatocellular carcinoma is not clear, but is intimately related to viral infection, environmental chemicals and hereditary factors. Many risk factors combine to cause carcinomas of the liver. The diagnosis of carcinoma, hepatocellular requires biopsy for pathology and immunohistochemical analyses for specific viral markers." - Anonymous Online Contributor
"Hepatic carcinoma, hepatocellular is a hard tumor that usually can not be cured. However, the long-term survival can be promoted when a cure for a hepatocellular carcinoma is obtained. The curative treatment of hepatocellular carcinoma must be developed." - Anonymous Online Contributor
"Carcinoma, hepatocellular, is a disease of the liver in which malignant tumor cells invade the liver. This tumor is relatively common in both non-Hispanic males and females over 30 years of age in the US and can have a devastating effect on the patient and his/her family." - Anonymous Online Contributor
"The study concludes that new anti-cancer drugs will be developed in the near future for hepatocellular carcinoma. It shows that gene therapy (silent gene therapy) and gene editing technologies may be used in hepatocellular carcinoma therapy in the future." - Anonymous Online Contributor
"Durvalumab significantly improves P-QOL, TFI and QWL in patients with advanced HCCs. It also improves WPRQOL and QWBQOL. Durvalumab has the potential to be an effective treatment for those with advanced HCC." - Anonymous Online Contributor
"The safety and efficacy of durvalumab were demonstrated in two pivotal phase III trials. Durvalumab may benefit patients with advanced or metastatic HCC. The safety and efficacy of durvalumab were additionally demonstrated in two additional, smaller cohorts. Future clinical trials will confirm the safety and efficacy of further indications of durvalumab. In addition to its use in mHCC, we believe that durvalumab represents an important advance against advanced form of HCC." - Anonymous Online Contributor
"Durvalumab is a medication that is effective as an immunomodulatory agent in metastatic NSCLC. It is a monoclonal antibody targeted against PD-1 that is given by an intravenous injection. It is already being used in several cancers and is an exciting new treatment in cancer patients with metastatic NSCLC, particularly those with mismatch repair gene, bRAF, or ALK alterations." - Anonymous Online Contributor
"These data indicate that CCL18 and its receptor CCR3 expression might be the key mechanisms of cancer cell invasion of metastatic site, and that CCL18/CCR3 signaling may be an important target by which chemotherapy can control CCL18 and metastasis." - Anonymous Online Contributor
"It is rare on average for anyone to experience a first diagnosis of HCC at age 45 or under. A second HCC diagnosis can occur from age 35 to about 50 years with a peak rate around age 45 but the majority of patients experienced their first HCC diagnoses after age 40." - Anonymous Online Contributor